{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:03:58Z","timestamp":1770753838107,"version":"3.50.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.diabres.2020.108008","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:27:48Z","timestamp":1578500868000},"page":"108008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective"],"prefix":"10.1016","volume":"160","author":[{"given":"Bianca","family":"Rocca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108008_b0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2337\/diab.25.7.566","article-title":"Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945\u20131970","volume":"25","author":"Palumbo","year":"1976","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2020.108008_b0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.2.2.120","article-title":"Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study","volume":"2","author":"Kannel","year":"1979","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108008_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2020.108008_b0020","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1161\/CIRCULATIONAHA.118.037454","article-title":"Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus","volume":"139","author":"Rawshani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2020.108008_b0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0030","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tem.2019.05.003","article-title":"Platelets as potent signaling entities in type 2 diabetes mellitus","volume":"30","author":"Pretorius","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabres.2020.108008_b0040","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1753-0407.12521","article-title":"Macro- and microvascular endothelial dysfunction in diabetes","volume":"9","author":"Shi","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2020.108008_b0045","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Davi","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0050","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2020.108008_b0055","article-title":"Nutrient metabolism, subcellular redox state, and oxidative stress in pancreatic islets and beta-cells","author":"Roma","year":"2019","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.diabres.2020.108008_b0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.diabres.2020.108008_b0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Ascend Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0070","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2020.108008_b0075","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/dmrr.2625","article-title":"Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis","volume":"31","author":"Zaccardi","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2020.108008_b0085","doi-asserted-by":"crossref","DOI":"10.1177\/1479164119844691","article-title":"Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus","author":"Gkaliagkousi","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.diabres.2020.108008_b0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/09537104.2013.777951","article-title":"Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA","volume":"25","author":"Lundstrom","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.diabres.2020.108008_b0095","first-page":"e3232","article-title":"In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance","author":"Santilli","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabres.2020.108008_b0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1160\/TH04-02-0118","article-title":"Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose","volume":"92","author":"Schafer","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/db15-0936","article-title":"In vivo platelet activation and aspirin responsiveness in type 1 diabetes","volume":"65","author":"Zaccardi","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2020.108008_b0110","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/01.ATV.17.4.802","article-title":"Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis","volume":"17","author":"Brown","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2020.108008_b0115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.numecd.2017.06.016","article-title":"Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case-control study","volume":"27","author":"Zaccardi","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.diabres.2020.108008_b0120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0125","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1161\/ATVBAHA.112.255281","article-title":"Platelets derived from the bone marrow of diabetic animals show dysregulated endoplasmic reticulum stress proteins that contribute to increased thrombosis","volume":"32","author":"Hernandez Vera","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2020.108008_b0130","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.celrep.2017.10.086","article-title":"Deletion of GLUT1 and GLUT3 reveals multiple roles for glucose metabolism in platelet and megakaryocyte function","volume":"21","author":"Fidler","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.diabres.2020.108008_b0135","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2337\/db18-0981","article-title":"Glucose metabolism is required for platelet hyperactivation in a murine Model of type 1 diabetes","volume":"68","author":"Fidler","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2020.108008_b0140","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3389\/fphar.2019.01244","article-title":"Measurement of thromboxane biosynthesis in health and disease","volume":"10","author":"Patrono","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2020.108008_b0145","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","article-title":"The platelet in diabetes: focus on prevention of ischemic events","volume":"26","author":"Colwell","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108008_b0150","article-title":"Pathophysiology of thrombosis in peripheral artery disease","author":"Habib","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.diabres.2020.108008_b0155","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3324\/haematol.2011.054916","article-title":"Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes","volume":"97","author":"Gerrits","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.diabres.2020.108008_b0160","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1159\/000452512","article-title":"Cell-derived microparticles in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.diabres.2020.108008_b0165","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/09537104.2018.1445837","article-title":"Meal intake increases circulating procoagulant microparticles in patients with type 1 and type 2 diabetes mellitus","volume":"30","author":"Spectre","year":"2019","journal-title":"Platelets"},{"issue":"8","key":"10.1016\/j.diabres.2020.108008_b0170","doi-asserted-by":"crossref","first-page":"e003553","DOI":"10.1161\/JAHA.116.003553","article-title":"Thrombin generation and atherothrombosis: what does the evidence indicate?","volume":"5","author":"Ten Cate","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2020.108008_b0175","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1538-7836.2008.03185.x","article-title":"Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb\/IIIa inhibition","volume":"6","author":"Razmara","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0180","doi-asserted-by":"crossref","first-page":"e55396","DOI":"10.1371\/journal.pone.0055396","article-title":"The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus","volume":"8","author":"Oggianu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.diabres.2020.108008_b0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2020.108008_b0190","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0195","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.2337\/db11-1806","article-title":"Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes","volume":"61","author":"Spectre","year":"2012","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2020.108008_b0200","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1160\/THS10-11-0739","article-title":"Inflammation and thrombosis in diabetes","volume":"105","author":"Hess","year":"2011","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.diabres.2020.108008_b0205","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/jth.14445","article-title":"Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation","volume":"17","author":"Petrucci","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.coph.2004.11.003","article-title":"Isoprostane formation and inhibition in atherothrombosis","volume":"5","author":"Patrono","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.diabres.2020.108008_b0215","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/01.CIR.101.24.2833","article-title":"Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo","volume":"101","author":"Audoly","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2020.108008_b0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0225","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2020.108008_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2020.108008_b0235","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC working group on thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2020.108008_b0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1160\/TH13-10-0844","article-title":"In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia","volume":"112","author":"Cavalca","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.diabres.2020.108008_b0245","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo","volume":"52","author":"Erlinge","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2020.108008_b0250","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","article-title":"Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel","volume":"50","author":"Payne","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.diabres.2020.108008_b0255","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2020.108008_b0260","doi-asserted-by":"crossref","first-page":"2134-41","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2020.108008_b0265","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2020.108008_b0270","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0275","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.diabres.2020.108008_b0280","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0285","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2020.108008_b0290","doi-asserted-by":"crossref","unstructured":"American Diabetes A. 10 Cardiovascular Disease and risk management: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S103\u2013S123.","DOI":"10.2337\/dc19-S010"},{"key":"10.1016\/j.diabres.2020.108008_b0295","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin Use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2020.108008_b0300","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2020.108008_b0305","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","article-title":"Role of aspirin in primary prevention of cardiovascular disease","volume":"16","author":"Patrono","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabres.2020.108008_b0310","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2020.108008_b0315","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2020.108008_b0320","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2020.108008_b0325","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","article-title":"Coronary calcium score and cardiovascular risk","volume":"72","author":"Greenland","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2020.108008_b0330","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2020.108008_b0335","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2020.108008_b0340","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2020.108008_b0345","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2020.108008_b0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2020.108008_b0355","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108008_b0360","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02520921."},{"key":"10.1016\/j.diabres.2020.108008_b0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2020.108008_b0370","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.diabres.2020.108008_bib371","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/CIRCULATIONAHA.116.026995","article-title":"Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus","volume":"136","author":"Hu","year":"2017","journal-title":"Circulation"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:10:39Z","timestamp":1759173039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":75,"alternative-id":["S0168822720300073"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108008","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108008"}}